Fycompa (Perampanel) Patent Expiration, LOE Window & CMS Spending
Fycompa (Perampanel) by Catalyst: FDA Orange Book core substance LOE 2026-07-01, 4 AB generics, $176.0M 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Catalyst |
| FDA Application & Pathway | N202834 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2026-07-01 |
| Last Listed Patent or Exclusivity Date | 2026-07-01 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $176.0M |
| 2024 Medicare Part D Spend | $75.7M |
| 2024 Medicaid Spend | $100.3M |
| Reported Wholesale Price Change (CA SB 17) | 14 WAC filings (max 16.5% 2-yr change) |